KR102091295B1 - 제약 제제 - Google Patents

제약 제제 Download PDF

Info

Publication number
KR102091295B1
KR102091295B1 KR1020147013457A KR20147013457A KR102091295B1 KR 102091295 B1 KR102091295 B1 KR 102091295B1 KR 1020147013457 A KR1020147013457 A KR 1020147013457A KR 20147013457 A KR20147013457 A KR 20147013457A KR 102091295 B1 KR102091295 B1 KR 102091295B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
oral pharmaceutical
solid oral
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147013457A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095500A (ko
Inventor
다야 베르마
요기타 크리쉬나마카리
시아오홍 쉔
한첸 이
핑 리
라진더 싱
레이추 탄
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47501412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102091295(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20140095500A publication Critical patent/KR20140095500A/ko
Application granted granted Critical
Publication of KR102091295B1 publication Critical patent/KR102091295B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147013457A 2011-11-23 2012-11-21 제약 제제 Active KR102091295B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
US61/563,229 2011-11-23
PCT/US2012/066185 WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
KR20140095500A KR20140095500A (ko) 2014-08-01
KR102091295B1 true KR102091295B1 (ko) 2020-03-19

Family

ID=47501412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147013457A Active KR102091295B1 (ko) 2011-11-23 2012-11-21 제약 제제

Country Status (38)

Country Link
US (4) US9387208B2 (enExample)
EP (2) EP2782557B1 (enExample)
JP (2) JP6216325B2 (enExample)
KR (1) KR102091295B1 (enExample)
CN (2) CN103945831A (enExample)
AR (1) AR088936A1 (enExample)
AU (1) AU2012340759C1 (enExample)
BR (1) BR112014011981B8 (enExample)
CA (1) CA2856406C (enExample)
CL (1) CL2014001337A1 (enExample)
CO (1) CO6940426A2 (enExample)
CY (1) CY1121421T1 (enExample)
DK (1) DK2782557T3 (enExample)
EA (1) EA025389B1 (enExample)
EC (1) ECSP23034537A (enExample)
ES (2) ES2695099T3 (enExample)
GT (1) GT201400100A (enExample)
HR (1) HRP20181896T1 (enExample)
HU (1) HUE040370T2 (enExample)
IL (1) IL232305B (enExample)
JO (1) JO3493B1 (enExample)
LT (1) LT2782557T (enExample)
MA (1) MA35716B1 (enExample)
MX (1) MX353446B (enExample)
MY (1) MY172729A (enExample)
PE (1) PE20141994A1 (enExample)
PH (1) PH12014501157A1 (enExample)
PL (1) PL2782557T3 (enExample)
PT (1) PT2782557T (enExample)
RS (1) RS58048B1 (enExample)
SG (1) SG11201401260QA (enExample)
SI (1) SI2782557T1 (enExample)
SM (1) SMT201800595T1 (enExample)
TN (1) TN2014000145A1 (enExample)
TW (1) TWI649098B (enExample)
UA (1) UA115039C2 (enExample)
WO (1) WO2013078264A1 (enExample)
ZA (1) ZA201402418B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN103917236A (zh) 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
CN113616606A (zh) 2015-06-04 2021-11-09 辉瑞公司 帕博西尼的固体剂型
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
DK3463345T3 (da) 2016-06-03 2023-01-09 Array Biopharma Inc Farmaceutiske kombinationer
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
MX2023003867A (es) 2020-10-05 2023-04-18 Pf Medicament Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023239337A1 (en) * 2022-06-08 2023-12-14 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising palbociclib
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
EP0952770A4 (en) * 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
HUP0001880A3 (en) 1997-05-22 2002-03-28 G D Searle & Co Chicago Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
CA2396380C (en) * 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN1906188A (zh) 2004-01-09 2007-01-31 诺瓦提斯公司 作为igf－1r抑制剂的苯基－[4－(3－苯基－1h－吡唑－4－基)－嘧啶－2－基]－胺衍生物
BRPI0511978A (pt) 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
CA2618377A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
WO2007022956A2 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
JP2009506040A (ja) 2005-08-26 2009-02-12 スミスクライン・ビーチャム・コーポレイション オーロラキナーゼのピリミジニル−ピラゾール阻害剤
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
EP2024353A2 (en) 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
BRPI0717805A2 (pt) 2006-10-06 2013-10-29 Irm Llc Inibidores de proteína quinase e métodos de uso dos mesmos
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EA201000113A1 (ru) 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
WO2009050291A2 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI0908906A2 (pt) 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
MX2011003740A (es) * 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Formulacion farmaceutica - 514.
US20110293750A1 (en) 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
ES2422263T3 (es) 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2786509C (en) 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CN103442715A (zh) 2011-03-21 2013-12-11 瓦尔库里亚公司 包括hdac抑制剂以及类固醇的药用组合物及其用途
MX344580B (es) 2011-06-14 2016-12-20 Novartis Ag Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
PE20141994A1 (es) 2011-11-23 2014-12-24 Novartis Ag Formulaciones farmaceuticas
HK1214765A1 (zh) 2012-11-08 2016-08-05 Novartis Ag 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Pharmaceutics and Biopharmacuetics, 50, 47-60쪽(2000)*

Also Published As

Publication number Publication date
ES2695099T3 (es) 2019-01-02
AU2012340759A1 (en) 2014-05-29
ZA201402418B (en) 2015-03-25
MY172729A (en) 2019-12-11
JP6216325B2 (ja) 2017-10-18
MX353446B (es) 2018-01-12
US20190054086A1 (en) 2019-02-21
NZ623628A (en) 2016-05-27
GT201400100A (es) 2017-09-28
TWI649098B (zh) 2019-02-01
AU2012340759C1 (en) 2019-11-28
AU2012340759B2 (en) 2016-04-28
US9763941B2 (en) 2017-09-19
CA2856406C (en) 2020-06-23
DK2782557T3 (en) 2018-12-10
JO3493B1 (ar) 2020-07-05
PE20141994A1 (es) 2014-12-24
KR20140095500A (ko) 2014-08-01
ES3037966T3 (en) 2025-10-08
EA025389B1 (ru) 2016-12-30
EP2782557B1 (en) 2018-09-12
HK1197024A1 (en) 2015-01-02
BR112014011981A2 (pt) 2017-05-30
HRP20181896T1 (hr) 2019-02-22
PL2782557T3 (pl) 2019-03-29
HUE040370T2 (hu) 2019-03-28
CN105708819A (zh) 2016-06-29
CN105708819B (zh) 2020-12-29
BR112014011981A8 (pt) 2018-07-31
TN2014000145A1 (en) 2015-09-30
AR088936A1 (es) 2014-07-16
US20160279129A1 (en) 2016-09-29
CL2014001337A1 (es) 2014-10-24
ECSP23034537A (es) 2023-08-31
TW201328722A (zh) 2013-07-16
UA115039C2 (uk) 2017-09-11
CO6940426A2 (es) 2014-05-09
EP3449911B8 (en) 2025-07-23
JP2018035171A (ja) 2018-03-08
LT2782557T (lt) 2018-12-27
SG11201401260QA (en) 2014-07-30
BR112014011981B8 (pt) 2022-07-19
BR112014011981B1 (pt) 2020-11-17
SI2782557T1 (sl) 2019-02-28
CA2856406A1 (en) 2013-05-30
IL232305A0 (en) 2014-06-30
US10561654B2 (en) 2020-02-18
EP2782557A1 (en) 2014-10-01
CN103945831A (zh) 2014-07-23
US20140309250A1 (en) 2014-10-16
MX2014006278A (es) 2014-07-09
EA201491007A1 (ru) 2014-08-29
JP2015501808A (ja) 2015-01-19
CY1121421T1 (el) 2020-05-29
US10258622B2 (en) 2019-04-16
MA35716B1 (fr) 2014-12-01
PH12014501157B1 (en) 2014-08-11
US20170202837A1 (en) 2017-07-20
PT2782557T (pt) 2018-11-26
PH12014501157A1 (en) 2014-08-11
EP3449911B1 (en) 2025-06-18
US9387208B2 (en) 2016-07-12
RS58048B1 (sr) 2019-02-28
WO2013078264A1 (en) 2013-05-30
EP3449911A1 (en) 2019-03-06
IL232305B (en) 2019-06-30
SMT201800595T1 (it) 2019-01-11

Similar Documents

Publication Publication Date Title
KR102091295B1 (ko) 제약 제제
ES2993251T3 (en) Pharmaceutical compositions of nilotinib
AU2008262059B2 (en) Stabilized amorphous forms of Imatinib mesylate
CN110114063B (zh) 鲁拉西酮固体分散体及其制备方法
EP3120871B1 (en) Solid dispersion
JP2015501808A5 (enExample)
HK40005622A (en) Pharmaceutical formulations
US20250017859A1 (en) Solid dispersion, preparation method, and pharmaceutical composition thereof
HK1197024B (en) Pharmaceutical formulations
NZ623628B2 (en) Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A)
CN120076794A (zh) 包含纳波拉非尼的无定形固体分散体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140520

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20171115

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171121

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190215

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190215

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191120

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190816

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20171121

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200120

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191120

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190816

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171121

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200313

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200313

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20211119

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 6

End annual number: 6